RU2705255C2 - Антитела против эотаксина 2, которые распознают дополнительные связывающие CCR3 хемокины - Google Patents

Антитела против эотаксина 2, которые распознают дополнительные связывающие CCR3 хемокины Download PDF

Info

Publication number
RU2705255C2
RU2705255C2 RU2016136639A RU2016136639A RU2705255C2 RU 2705255 C2 RU2705255 C2 RU 2705255C2 RU 2016136639 A RU2016136639 A RU 2016136639A RU 2016136639 A RU2016136639 A RU 2016136639A RU 2705255 C2 RU2705255 C2 RU 2705255C2
Authority
RU
Russia
Prior art keywords
antibody
seq
amino acid
eotaxin
acid sequence
Prior art date
Application number
RU2016136639A
Other languages
English (en)
Russian (ru)
Other versions
RU2016136639A (ru
RU2016136639A3 (enExample
Inventor
Ади МОР
Original Assignee
Хемомаб Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хемомаб Лтд. filed Critical Хемомаб Лтд.
Publication of RU2016136639A publication Critical patent/RU2016136639A/ru
Publication of RU2016136639A3 publication Critical patent/RU2016136639A3/ru
Application granted granted Critical
Publication of RU2705255C2 publication Critical patent/RU2705255C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
RU2016136639A 2014-03-04 2015-03-04 Антитела против эотаксина 2, которые распознают дополнительные связывающие CCR3 хемокины RU2705255C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461947852P 2014-03-04 2014-03-04
US61/947,852 2014-03-04
PCT/IL2015/050234 WO2015132790A2 (en) 2014-03-04 2015-03-04 Anti eotaxin-2 antibodies that recognize additional ccr3-binding chemokines

Publications (3)

Publication Number Publication Date
RU2016136639A RU2016136639A (ru) 2018-04-05
RU2016136639A3 RU2016136639A3 (enExample) 2018-05-04
RU2705255C2 true RU2705255C2 (ru) 2019-11-06

Family

ID=52815066

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016136639A RU2705255C2 (ru) 2014-03-04 2015-03-04 Антитела против эотаксина 2, которые распознают дополнительные связывающие CCR3 хемокины

Country Status (11)

Country Link
US (2) US10246508B2 (enExample)
EP (2) EP3114139B1 (enExample)
JP (1) JP6553075B2 (enExample)
CN (1) CN106103479B (enExample)
BR (1) BR112016020366B1 (enExample)
DK (1) DK3114139T3 (enExample)
ES (1) ES2926700T3 (enExample)
IL (1) IL247219B (enExample)
PT (1) PT3114139T (enExample)
RU (1) RU2705255C2 (enExample)
WO (1) WO2015132790A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2832323C1 (ru) * 2020-04-22 2024-12-23 Кемомаб Лтд. Способ лечения с использованием антитела против CCL24

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017183028A1 (en) * 2016-04-18 2017-10-26 Chemomab Ltd. Eotaxin-2 inhibitors in the treatment of fibromyalgia
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
EP3554541B1 (en) 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
ES3052981T3 (en) 2017-01-24 2026-01-16 Kyowa Kirin Co Ltd Therapeutic or prophylactic agent for treating radiation damage
GB201702500D0 (en) * 2017-02-16 2017-04-05 Univ Sheffield Stable vamp reporter assay
IL251024A0 (en) * 2017-03-08 2017-06-29 Chemomab Ltd Antibodies against eutaxin 2 for use in the treatment of liver diseases
EP3883635A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
WO2020185516A1 (en) 2019-03-08 2020-09-17 Auris Health, Inc. Tilt mechanisms for medical systems and applications tilt mechanisms for medical systems and applications tilt mechanisms for medical systems and applications tilt mechanisms for medical systems and applications tilt mechanisms for medical systems and
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
US20230192836A1 (en) 2020-04-20 2023-06-22 Chemomab Ltd. Ccl24 inhibitors in the treatment of covid-19
CN115427445A (zh) 2020-04-22 2022-12-02 彻莫马布有限公司 使用抗ccl24抗体的治疗方法
EP4143227A2 (en) * 2020-04-30 2023-03-08 Sairopa B.V. Anti-cd103 antibodies

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000027880A2 (en) * 1998-11-11 2000-05-18 Fondazione Centro San Raffaele Del Monte Tabor Rantes-derived peptides with anti-hiv activity
WO2010086854A1 (en) * 2009-01-28 2010-08-05 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Eotaxin-2 (ccl24) inhibitors in inflammatory, autoimmune, and cardiovascular disorders
RU2009101297A (ru) * 2006-07-22 2010-08-27 Оксаген Лимитед (GB) Соединения, обладающие антагонистической активностью по отношению к crth2
WO2011025962A1 (en) * 2009-08-28 2011-03-03 Dan Allison Antikine antibodies that bind to multiple cc chemokines
RU2013140619A (ru) * 2011-03-07 2015-04-20 Атопикс Терапьютикс Лимитед Аморфная (5-фтор-2-метил-3-хинолин-2-илметилиндол-1-ил)-уксусная кислота

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000027880A2 (en) * 1998-11-11 2000-05-18 Fondazione Centro San Raffaele Del Monte Tabor Rantes-derived peptides with anti-hiv activity
RU2009101297A (ru) * 2006-07-22 2010-08-27 Оксаген Лимитед (GB) Соединения, обладающие антагонистической активностью по отношению к crth2
WO2010086854A1 (en) * 2009-01-28 2010-08-05 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Eotaxin-2 (ccl24) inhibitors in inflammatory, autoimmune, and cardiovascular disorders
WO2011025962A1 (en) * 2009-08-28 2011-03-03 Dan Allison Antikine antibodies that bind to multiple cc chemokines
RU2013140619A (ru) * 2011-03-07 2015-04-20 Атопикс Терапьютикс Лимитед Аморфная (5-фтор-2-метил-3-хинолин-2-илметилиндол-1-ил)-уксусная кислота

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2832323C1 (ru) * 2020-04-22 2024-12-23 Кемомаб Лтд. Способ лечения с использованием антитела против CCL24

Also Published As

Publication number Publication date
US20190153088A1 (en) 2019-05-23
IL247219A0 (en) 2016-09-29
EP4155317A1 (en) 2023-03-29
PT3114139T (pt) 2022-09-13
WO2015132790A3 (en) 2015-11-05
WO2015132790A2 (en) 2015-09-11
DK3114139T3 (da) 2022-09-12
JP6553075B2 (ja) 2019-08-07
JP2017508461A (ja) 2017-03-30
ES2926700T3 (es) 2022-10-27
US20160368979A1 (en) 2016-12-22
CN106103479A (zh) 2016-11-09
US10479830B2 (en) 2019-11-19
EP3114139A2 (en) 2017-01-11
RU2016136639A (ru) 2018-04-05
US10246508B2 (en) 2019-04-02
EP3114139B1 (en) 2022-06-15
BR112016020366A2 (pt) 2018-06-05
RU2016136639A3 (enExample) 2018-05-04
IL247219B (en) 2021-09-30
CN106103479B (zh) 2019-12-24
BR112016020366B1 (pt) 2024-01-02

Similar Documents

Publication Publication Date Title
RU2705255C2 (ru) Антитела против эотаксина 2, которые распознают дополнительные связывающие CCR3 хемокины
JP7671699B2 (ja) 抗ＴｒｋＡ抗体及びその使用
JP2023537422A (ja) Ｉｌ－１１の抗体及びその使用
JP7419262B2 (ja) 抗ｐｃｓｋ９抗体を含む製剤およびその使用
JP6900051B2 (ja) Ｃｌａｕｄｉｎ ５抗体、及びその抗体を含有する医薬
TW202140554A (zh) 用於治療腎臟疾病之抗αｖβ８整聯蛋白抗體
CN109384845A (zh) 一种cd40单克隆抗体、其制备方法及其应用
US20220372126A1 (en) Anti ccl24 (eotaxin2) antibodies for use in the treatment of hepatic diseases
KR20140138699A (ko) 염증 질환 치료제
KR20230142834A (ko) 항-cd38 항체 및 이의 용도
US20230192836A1 (en) Ccl24 inhibitors in the treatment of covid-19
JP7202011B2 (ja) 抗ｒａｍｐ２抗体
IL298894A (en) Human anti-grp94 antibodies and uses
HK40128853A (zh) 抗人cd300a单克隆抗体及其抗原结合片段
WO2024224915A1 (ja) 抗ヒトｃｄ３００ａモノクローナル抗体およびその抗原結合性断片
WO2017183028A1 (en) Eotaxin-2 inhibitors in the treatment of fibromyalgia
CN113164601A (zh) 一种分离的抗原结合蛋白及其用途
CN113166264A (zh) 一种分离的抗原结合蛋白及其用途